Why is Unjha Formulations Ltd falling/rising?

Recent Price Action and Market Context

Unjha Formulations opened the day with a gap down of 4.53%, signalling immediate bearish sentiment among traders. Throughout the session, the stock traded within a wide range of ₹2.25, with the weighted average price skewed towards the lower end, indicating that more volume was transacted near the day's lows. The stock also experienced high intraday volatility of 5.56%, underscoring the uncertainty and nervousness among investors. Notably, the share price is currently trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a sustained downtrend.

In comparison, the Pharmaceuticals & Drugs sector, to which Unjha Formulations belongs, declined by 3.58% on the same day, suggesting that the stock’s underperformance was more severe than the sector average. This underperformance is further highlighted by the stock’s relative returns over various time frames. Over the past week, Unjha Formulations fell by 8.65%, more than double the Sensex’s decline of 3.72%. Over one month, the stock dropped 13.68%, slightly worse than the Sensex’s 12.72% fall. Year-to-date, the stock has plummeted 24.00%, significantly underperforming the Sensex’s 14.70% decline. Over the last year, the stock’s return was -19.83%, compared to the Sensex’s modest -5.47%, indicating persistent weakness relative to the broader market.

Fundamental Challenges and Investor Sentiment

Despite the recent price weakness, Unjha Formulations exhibits some attractive valuation metrics. The company boasts a return on equity (ROE) of 33.1%, which is considered very strong, and trades at a price-to-book value of 2.7, indicating a discount relative to its peers’ historical valuations. Furthermore, the company’s profits have risen by 41% over the past year, and its price/earnings-to-growth (PEG) ratio stands at a low 0.1, suggesting that the stock may be undervalued on a growth-adjusted basis.

However, these positives are overshadowed by several fundamental concerns. The company’s long-term operating profit growth has been modest, with a compound annual growth rate (CAGR) of 15.77% over the last five years, which is considered weak for sustaining investor confidence. Additionally, the firm’s ability to service its debt is poor, as reflected by an average EBIT to interest ratio of just 0.54, signalling potential financial stress. The flat financial results reported in December 2025 have also failed to inspire confidence among shareholders.

Investor participation has notably declined, with delivery volumes on 20 March falling by over 80% compared to the five-day average, indicating reduced buying interest. This diminished engagement, combined with the stock’s liquidity profile, suggests that investors are cautious and possibly exiting positions amid the ongoing downtrend.

Comparative Performance and Market Outlook

Over a longer horizon, Unjha Formulations has delivered strong returns, with gains of 47.40% over three years and an impressive 126.19% over five years, outperforming the Sensex’s respective returns of 25.50% and 45.24%. This indicates that the company has demonstrated growth potential historically. Nevertheless, the recent underperformance relative to the broader market and sector, coupled with weak fundamentals and falling investor interest, has weighed heavily on the stock price in the short term.

In summary, the sharp decline in Unjha Formulations Ltd’s share price on 23 March is primarily driven by a combination of weak recent market performance, poor investor participation, and fundamental concerns around debt servicing and profit growth. While valuation metrics and historical returns offer some optimism, the prevailing negative sentiment and technical indicators suggest continued caution among investors.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →